GlassScriptPhysician profile
Angela Intili
NPI 1114080033
$4,760.90
in general payments reported to CMS, 2019-2025
26 companies · $358 in 2025
The $358 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $706 · 2020: $152 · 2021: $909 · 2022: $1,090 · 2023: $1,155 · 2024: $391 · 2025: $358.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,904.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,903.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $1,257.29 | 2021-2023 | |
| Abbvie INC. | $778.28 | 2019-2023 | |
| Hologic Sales and Service, LLC | $360.01 | 2021-2025 | Acessa Provu System, Coolseal Generator, Myosure Tissue Removal Device |
| Agile Therapeutics, INC. | $291.61 | 2021-2024 | Twirla |
| Mayne Pharma Commercial LLC | $241.79 | 2021-2025 | |
| Allergan, INC. | $237.71 | 2019-2022 | |
| Aimmune Therapeutics, INC. | $213.67 | 2024-2025 | Zenpep |
| Pfizer INC. | $209.93 | 2019-2025 | |
| Therapeuticsmd, INC. | $177.88 | 2019-2022 | |
| Avion Pharmaceuticals | $155.53 | 2020-2023 | Balcoltra |
| Exeltis, USA INC. | $148.32 | 2019-2025 | Slynd |
| Astellas Pharma US INC | $130.50 | 2023-2025 | Veozah |
| Galderma Laboratories, L.P. | $111.05 | 2019 | |
| Exact Sciences Corporation | $92.20 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Duchesnay USA Incorporated | $62.56 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evofem Biosciences, INC. | $44.40 | 2021-2022 | |
| Myovant Sciences INC. | $42.83 | 2022 | |
| Scynexis, INC. | $41.77 | 2022 | |
| Amag Pharmaceuticals, INC. | $41.03 | 2019 | |
| Alfasigma USA, INC. | $24.14 | 2020 | |
| Vertical Pharmaceuticals, LLC | $22.94 | 2019 | |
| Lilly USA, LLC | $17.57 | 2021 | |
| Millicent US INC | $17.44 | 2025 | Intrarosa |
| Boston Scientific Corporation | $15.69 | 2019 | |
| Organon LLC | $13.73 | 2025 | Nexplanon |
| Lupin INC. | $11.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Intili listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.